Idexx Laboratories(NASDAQ) IDXX

IDEXX makes tools that help veterinarians check the health of pets through blood and urine tests. They also provide testing kits to keep drinking water safe and livestock healthy. Their products give doctors and farmers fast, accurate results to treat animals better.

The Diagnostic Toolkit

• Companion Animal Group: Provides point-of-care analyzers, rapid test kits, and reference laboratory services for pets; also includes practice management software and digital imaging systems.
• Water Quality Products: Offers tests that detect bacterial contaminants like E. coli and coliforms in water; used by utilities and labs to meet safety standards.
• Livestock, Poultry and Dairy: Produces diagnostic tests to manage herd health and screening tools to ensure the quality and safety of milk.
• Human Medical Diagnostics: Sells point-of-care blood gas and electrolyte analyzers used in human hospitals and clinics.

New Tools and Targets

• Launched the IDEXX Cancer Dx Panel in North America during 2025 to help veterinarians screen dogs for lymphoma through blood tests.
• Introduced the IDEXX inVue Dx Cellular Analyzer in late 2024, which uses artificial intelligence to automate cytology testing in clinics.
• Released the ImageVue DR50 Plus in North America in January 2026 to provide high-definition digital X-rays with lower radiation doses.
• Expanded the UV Viewer Plus bench-top cabinet in 2025 to help laboratory technicians read fluorescent-based water tests more easily.

What Makes IDEXX Different

The company maintains a global network of roughly 80 reference laboratories and employs over 11,000 people across 34 countries. Their competitive edge comes from integrating diagnostic hardware with cloud-based software, allowing veterinarians to see all patient data in one digital file.

The Recent Numbers

• Revenue reached $1.1 billion in Q4 2025, representing a 14.3% increase from Q4 2024.
• Net income rose to $248.2 million in Q4 2025, up 14.8% from the $216.1 million reported in Q4 2024.
• Free cash flow grew to $322.6 million in Q4 2025, a 44.8% jump year-over-year.
• Operating income hit $315.6 million in Q4 2025, up 20.6% compared to $261.7 million in Q4 2024.

Bottom Line

IDEXX has grown from a specialized testing firm into a global leader in veterinary technology and water safety. Its shift toward cloud-based software and artificial intelligence continues to change how animal healthcare providers manage their daily operations.